No benefit with adjuvant vitamin D in MS: meta-analysis
February 12, 2024…in the SOLAR trial of interferon-β and adjunctive high-dose vitamin D (14,000 IU/day) (Hupperts et al. Neurology 2019;93:e1906-e1916). The proportion of patients achieving no evidence of disease activity (NEDA) at 48 weeks was 36.3% with vitamin D and 35.3% without vitamin D, although MRI outcomes (combined unique active lesions, T2 lesion volume) were improved with add-on therapy. A subsequent SOLAR subgroup analysis found that higher serum 25(OH…